Professor, Hematology and Medical Oncology, Emory University School of Medicine
Hematology
Dr. Hanna J. Khoury, MD
|
|
Give Review
Hanna J. Khoury, MD practices Hematology. Doctor Hanna J. Khoury, MD is a published doctor and has 63 publications published. The lastest was: 'Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia.' Hanna Khoury accepts all Medicare patients.
Publications
- Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
- Allogeneic hematopoietic cell transplantation for patients with mixed phenotype Acute leukemia.
- 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgki...
- Factors influencing long-term efficacy and tolerability of bosutinib in Chronic phase Chronic myeloid leukaemia resistant or intolerant to imatinib.
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- Outcomes of chronic-phase chronic myeloid Leukemia beyond first-line therapy.
- Open pipelines for integrated tumor genome profiles reveal differences between pancreatic Cancer tumors and cell lines.
- Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed Acute leukemia or high-risk myelodysplastic syndrome.
- Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
- The role of observational studies in optimizing the clinical management of chronic myeloid Leukemia.
- Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid Leukemia: Results with 24 months ...
- Omacetaxine mepesuccinate in patients with advanced chronic myeloid Leukemia with resistance or intolerance to tyrosine kinase inhibitors.
- Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan or TBI.
- Predicting early blast transformation in chronic-phase chronic myeloid Leukemia: Is immunophenotyping the missing link?
- Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate.
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
- Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the warburg effect.
- Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid Leukemia.
- Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth.
- Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leu...
- Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia.
- Bosutinib treatment for Philadelphia chromosome-positive Leukemias.
- Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex.
- Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous Leukemia: an overview.
- Bosutinib safety and management of toxicity in Leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
- In vivo T cell costimulation blockade with abatacept for Acute graft-versus-host disease prevention: a first-in-disease trial.
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias.
- Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic Cell transplants from partially mismatched unrelated donors.
- Advances in hematopoietic stem cell transplantation in chronic myeloid Leukemia.
- Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid Leukemia previously treated with 2 or more tyrosine kinase inhibitors including i...
- Temporal changes in plerixafor administration and hematopoietic stem Cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
- Autologous haematopoietic cell transplantation for non-Hodgkin Lymphoma with secondary CNS involvement.
- Epsilon aminocaproic acid prevents bleeding in severely Thrombocytopenic patients with hematological malignancies.
- Venous access catheter-related thrombosis in patients with Cancer.
- Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulati...
- Tools to optimize the functionality of a Leukemia clinical trial team.
- A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with Lymphoma.
- Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
- Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?
- Managing Chronic Myeloid Leukemia: A Coordinated Team Care Perspective.
- A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid Leukemias.
- Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgk...
- Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML Cells with mutant NPM1.
- p90RSK2 is essential for FLT3-ITD-, but dispensable for BCR-ABL-induced myeloid Leukemia.
- Peripheral blood monitoring of chronic myeloid Leukemia during treatment with imatinib, second-line agents, and beyond.
- Generic immunosuppressants in hematopoietic Cell transplantation.
- Reducing the risk for transplantation-related mortality after allogeneic hematopoietic Cell transplantation: how much progress has been made?
- Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for Acute myeloid leukemia in first remission with unfavorable cytogeneti...
- Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations.
- Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid Leukemia.
- Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.
- A randomized double-blind trial of hydroxychloroquine for the prevention of Chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
- FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
- 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic Cells.
- Long-term remissions in patients with myelodysplastic syndrome and secondary Acute myelogenous leukemia undergoing allogeneic transplantation following a reduced inten...
- Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem Cell transplantation.
- Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's Lymphoma.
- Donor CMV serostatus has no impact on CMV viremia or Disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell trans...
- Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid Leukemia.
- Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Schools
Universite Catholique De Louvain Faculte De Medecine
Meml Med Center
Washington University
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Washington University
Hospital
-
Emory University Hospital -
Emory University Hospital Midtown -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1912014655 | |
| NPPES Provider LastName | KHOURY | |
| NPPES Provider FirstName | HANNA | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 836.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 1.79 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912014655 |
| Last Name Of The Provider | KHOURY |
| First Name Of The Provider | HANNA |
| View All |
Similar Doctors
|
|
Dr. Torey B. Clark, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael P. Fanucchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Eckman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamal N. Ummed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan L. Kaufman, MD |
|
|
Dr. Dong M. Shin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Wendy M. Baer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn E. Ezell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myra E. Rose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Casey E. Gooden, MD |
|
|
Dr. Aaron Tomer, MD |
|
|
Dr. Robert L. Stahl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Elyse W. Bryson, PA-C |